By contrast, currently, the outcome of checkpoint blockade with PD-1/PD-L1 inhibitors alone is unsatisfactory in MM, compared with HL or solid tumors due to the reduced immune dysfunction in MM [200]. The gene discussed is CD274; the disease is Hodgkins lymphoma.